VLA Stock Overview
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Valneva SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.10 |
| 52 Week High | €8.00 |
| 52 Week Low | €2.97 |
| Beta | 0.83 |
| 1 Month Change | -16.44% |
| 3 Month Change | -23.36% |
| 1 Year Change | -36.08% |
| 3 Year Change | -74.23% |
| 5 Year Change | -7.19% |
| Change since IPO | -43.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| VLA | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | -16.9% | -3.0% | -0.6% |
| 1Y | -36.1% | -12.4% | 1.8% |
Return vs Industry: VLA underperformed the Austrian Biotechs industry which returned -12.4% over the past year.
Return vs Market: VLA underperformed the Austrian Market which returned 1.8% over the past year.
Price Volatility
| VLA volatility | |
|---|---|
| VLA Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in AT Market | 5.4% |
| 10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: VLA's share price has been volatile over the past 3 months.
Volatility Over Time: VLA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 676 | Thomas Lingelbach | valneva.com |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Valneva SE Fundamentals Summary
| VLA fundamental statistics | |
|---|---|
| Market cap | €513.51m |
| Earnings (TTM) | -€101.43m |
| Revenue (TTM) | €153.71m |
3.3x
P/S Ratio-5.1x
P/E RatioIs VLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VLA income statement (TTM) | |
|---|---|
| Revenue | €153.71m |
| Cost of Revenue | €160.77m |
| Gross Profit | -€7.06m |
| Other Expenses | €94.37m |
| Earnings | -€101.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -0.73 |
| Gross Margin | -4.59% |
| Net Profit Margin | -65.99% |
| Debt/Equity Ratio | 137.9% |
How did VLA perform over the long term?
See historical performance and comparison